Thairm Bio

Thomas H. Haire is the principal associated with Thairm Bio. Public filings and corporate records link him directly to the entity's investment activity. The firm does not publish a broader investment committee or list additional managing directors.

Thairm Bio concentrates on biotechnology, including therapeutics, drug-development platforms, and enabling life-sciences technologies. Its disclosed investments, such as WindMIL Therapeutics, fall squarely in the clinical-stage oncology space. The firm does not appear to allocate to consumer tech, real estate, or traditional private equity.

The office primarily participates in direct equity rounds, often at the early or clinical stage, rather than committing to external venture funds as a limited partner. Its investment posture resembles a permanent-capital vehicle linked to a family balance sheet, prioritizing long holding periods over fund-cycle liquidity constraints.

The firm's exact structure is not publicly defined, but its operations are consistent with a single-family office or a closely held pooled investment vehicle run by Thomas Haire. No evidence suggests an open architecture accepting external families as clients.

Thairm Bio's disclosed investments and physical footprint center on the Mid-Atlantic biotech corridor, particularly the Baltimore-Washington region and Pennsylvania. The office has shown willingness to participate in syndicates that extend to Boston and other US life-sciences hubs.